An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
19 11 2020
Historique:
received: 01 04 2020
accepted: 11 05 2020
pubmed: 15 5 2020
medline: 15 12 2020
entrez: 15 5 2020
Statut: ppublish

Résumé

Increased production of inflammatory cytokines and myeloid-derived suppressor cells occurs in patients with coronavirus disease 2019. These inversely correlated with perforin-expressing natural killer (NK) and CD3+ T cells. We observed a lower number of perforin-expressing NK cells in intensive care unit (ICU) patients compared with non-ICU patients, suggesting an impairment of the immune cytotoxic arm as a pathogenic mechanism.

Identifiants

pubmed: 32407466
pii: 5837139
doi: 10.1093/cid/ciaa577
pmc: PMC7239202
doi:

Substances chimiques

Cytokines 0
Perforin 126465-35-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2272-2275

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Blood. 2002 Jan 1;99(1):61-6
pubmed: 11756153
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Lancet. 2020 Mar 28;395(10229):1063-1077
pubmed: 32145185
J Virol. 2014 Aug;88(15):8479-89
pubmed: 24829345
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Microbiol. 2019 May 10;10:1057
pubmed: 31134045
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
Arthritis Rheumatol. 2015 Nov;67(11):3037-46
pubmed: 26251193
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188

Auteurs

Veronica Bordoni (V)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Alessandra Sacchi (A)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Eleonora Cimini (E)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Stefania Notari (S)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Germana Grassi (G)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Eleonora Tartaglia (E)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Rita Casetti (R)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Maria Letizia Giancola (ML)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Nazario Bevilacqua (N)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Markus Maeurer (M)

Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal.
I Med Clinic, University of Mainz, Mainz, Germany.

Alimuddin Zumla (A)

Division of Infection and Immunity, University College London, London, United Kingdom.
National Institute of Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Franco Locatelli (F)

Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Fabrizio De Benedetti (F)

Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Fabrizio Palmieri (F)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Luisa Marchioni (L)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Maria R Capobianchi (MR)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Gianpiero D'Offizi (G)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Nicola Petrosillo (N)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Andrea Antinori (A)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Emanuele Nicastri (E)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Giuseppe Ippolito (G)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Chiara Agrati (C)

National Institute for Infectious Diseases Lazzaro Spallanzani, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH